Customizing Treatment Plans for the Diabetic Patient - On-demand

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals.

Learning Objectives

Upon completion of this activity, the participant should be able to:

• Discuss the benefits of consistent anti-VEGF treatment.
• Explain why patients with diabetic retinopathy (DR) and diabetic macular edema (DME) are so often lost to follow-up.
• Execute patient education plans on the importance of frequent DME treatment to improve treatment and exam compliance.
• Apply best practices and strategies in a cross-disciplinary approach to diabetes management to better manage patients.

Accreditation and Designation Statement

This educational activity is provided by Evolve Medical Education LLC (Evolve).

Accreditation Statement Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation Statement Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Allen C. Ho, MD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Adverum, Aerie Pharmaceuticals, AGTC, Alcon Vision, Aldeyra, Allergan, Apellis, Asclepix, Beaver-Visitec International, Chengdu Kanghong Biotechnology, Genentech, RegenXBio, MeiraGTx, Gyroscope, Clearside, Iveric/Ophthotech, Janssen/Johnson & Johnson Vision, Lineage, Notal Vision, Ocular Therapeutics, ONL, Regeneron Pharmaceuticals. Grant/Research Support: Adverum, Aerie Pharmaceuticals, AGTC, Alcon Vision, Aldeyra, Allergan, Apellis, Asclepix, Chengdu Kanghong Biotechnolog, Genentech, Graybug, Gyroscope, Iveric/Ophthotech, Janssen/Johnson & Johnson Vision, Lineage, Lumithera, MeiraGTx, National Eye Institute, Notal Vision, Novartis, ProQR, Regeneron Pharmaceuticals, and RegenXBio. Other support: Covalent.

John W. Kitchens, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Alimera, Allergan, Bayer, Carl Zeiss Meditec, Genentech, Kodiak Sciences, and Regeneron Pharmaceuticals. Grant/Research Support: Kodiak Sciences. Speaker's Bureau: Bayer, Genentech, and Regeneron Pharmaceuticals.

The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron Pharmaceuticals.